SUNNYVALE, Calif., Feb. 14, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today the completion of the annual CyberKnife Scientific Meeting held February 10-12, 2011, in San Francisco, Calif. The global event hosted over 340 users of the CyberKnife® Robotic Radiosurgery System representing 12 countries. The three-day meeting brought together surgeons, radiation oncologists, therapists, medical physicists and other associated professionals to share the latest scientific data and exchange information about the use of the CyberKnife System to treat a broad range of malignant and benign tumors.
"It has been a pivotal year for the CyberKnife System, with new and exciting research published and presented in the fields of lung, prostate and breast cancer, and continued significant growth in clinical adoption worldwide across all clinical indications," said Omar Dawood, vice president of global medical affairs at Accuray. "We are proud to sponsor annual scientific meetings for CyberKnife users, such as this year's CyberKnife Summit, to facilitate the exchange of clinical and technical experiences with the common goal of furthering the field of full body radiosurgery."
This year's meeting featured clinical and technical presentations on a broad range of CyberKnife indications including prostate, lung, liver, breast, spine and brain tumors. Many of these presentations focused on the long term outcomes following CyberKnife radiosurgery as well as quality of life benefits.
As in past years, this year's summit also featured a session focused on Performance Improvement case reviews and Patient Safety. This session was sponsored by the University of Pittsburgh Cancer Institute designed to create an open forum for discussion of treatment experiences to ensure patient safety and the highest level of care surrounding the use of the CyberKnife System. Practicing CyberKnife specialists shared experiences and insights to help improve the management and patient care of CyberKnife treatments.
To review additional details from this year's CyberKnife Summit click here.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 222 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical experience, clinical results and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, clinical results and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2010 fiscal year, our form 10-Q filed on January 27, 2011 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Euan Thomson, Ph.D.
Omar Dawood, M.D., MPH
SOURCE Accuray Incorporated